Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2

被引：0
|
作者：
Armstrong, April W. [1 ]
Liu, Yan [2 ]
Li, Nan [2 ]
Reich, Kristian [3 ]
Foley, Peter [4 ,5 ]
Li, Shu [6 ]
Fakharzadeh, Steven [2 ,6 ]
Papp, Kim A. [7 ,8 ]
Han, Chenglong [2 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA 90007 USA
[2] Janssen Global Serv LLC, Raritan, NJ USA
[3] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[4] Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Vic, Australia
[5] Skin Hlth Inst, Prob Med Res, Carlton, Vic, Australia
[6] Janssen Res & Dev LLC, Raritan, NJ USA
[7] K Papp Clin Res, Waterloo, ON, Canada
[8] Prob Med Res Inc, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27078
引用
收藏
页码：AB128 / AB128
页数：1
相关论文
共 50 条
  • [31] EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS
    Gordon, K.
    Merola, J. F.
    Foley, P.
    Choi, O.
    Chan, D.
    Miller, M.
    You, Y.
    Shen, Y. K.
    Yang, Y. W.
    Blauvelt, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1842 - 1842
  • [32] Safety in patients with latent tuberculosis (TB) treated with guselkumab and anti-TB treatments in the phase 3 VOYAGE 1 and 2 trials for moderate-to-severe plaque psoriasis
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 41 - 42
  • [33] Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis
    Reich, Kristian
    Sinclair, Rodney
    Roberts, Graeme
    Griffiths, Christopher E. M.
    Tabberer, Maggie
    Barker, Jonathan
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1237 - 1254
  • [34] Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study
    Gordon, K. B.
    Armstrong, A. W.
    Han, C.
    Foley, P.
    Song, M.
    Wasfi, Y.
    You, Y.
    Shen, Y. -K.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (11) : 1940 - 1949
  • [35] Effect of ixekizumab treatment on scalp psoriasis: Results from a phase 2 study in patients with moderate to severe psoriasis
    Langley, Richard
    Zhu, Baojin
    Leonardi, Craig
    Edson-Heredia, Emily
    Cameron, Gregory
    Erickson, Janelle
    Heffernan, Michael
    Maeda-Chubachi, Tomoko
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB168 - AB168
  • [36] Efficacy responses across disease severity and treatment history subgroups of patients with moderate to severe plaque psoriasis treated with guselkumab: Pooled results from VOYAGE 1&2 through 5 years
    Gordon, Kenneth B.
    Merola, Joseph F.
    Foley, Peter
    Choi, Olivia
    Chan, Daphne
    Miller, Megan
    You, Yin
    Shen, Yaung-Kaung
    Yang, Ya-Wen
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB163 - AB163
  • [37] Ustekinumab Improves Health-Related Quality of Life in Korean and Taiwanese Patients With Moderate to Severe Psoriasis: Results from the PEARL Trial
    Tsai, Tsen-Fang
    Song, Michael
    Shen, Yaung-Kaung
    Schenkel, Brad
    Choe, Yong-Beom
    Kim, Nack-In
    Lee, Joo-Heung
    Lee, Ju-Hee
    Song, Hae-Jun
    Youn, Jai-Il
    JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (08) : 943 - 949
  • [38] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [39] Patient-reported symptoms and signs in patients with moderate-severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1, a phase III clinical trial
    Blauvelt, Andrew
    Papp, Kim
    Griffiths, Christopher E. M.
    Han, Chenglong
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Kimball, Alexa B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB191 - AB191
  • [40] P94 Bimekizumab early treatment response translated into cumulative benefits in health-related quality of life in patients with moderate-to-severe plaque psoriasis: results from 2years of the BE RADIANT phase IIIb trial
    Hampton, Philip
    Brunner, Patrick
    Ghoreschi, Kamran
    Boehncke, Wolf-Henning
    Warham, Rhys
    Ciaravino, Valerie
    Szilagyi, Balint
    Staelens, Fabienne
    Foulkes, Amy
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345